country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-183256

Copy Link Print Information

BAY-7728

BAY-7728 is an orally active and selective dual inhibitor of KAT6A (IC₅₀: 45 nM)/KAT6B (IC₅₀: 95 nM). BAY-7728 can effectively inhibit tumor growth and regulate the acetylation level of histone H3K23. BAY-7728 can be used for tumor research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 2767642-46-4
Formule: C₂₀H₁₉FN₂O₅S
Masse moléculaire:418.44

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

BAY-7728 Chemical Structure

CAS No.: 2767642-46-4

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Pureté et documentation
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform Histone Acetyltransferase :

In Vitro

BAY-7728 exhibits IC₅₀ values of 55 nM and 164 nM against MVLN and ZR75-1 cells, respectively.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

BAY-7728 (2.5-100 mg/kg; oral administration; once daily; 22 days) reduces intratumoral H3K23ac levels and inhibits tumor growth in a dose-dependent manner without obvious dose-limiting toxicity in NMRI nude mice bearing LCLC-97TM1 human lung cancer xenografts.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NMRI nude mice bearing established LCLC-97TM1 human lung cancer xenografts
Dosage:

2.5-100 mg/kg
Administration:

Oral, once daily, for 22 consecutive days
Result:

Demonstrated dose-dependent inhibition of tumor growth and reduction of intratumoral histone H3K23 acetylation (H3K23ac) levels in the LCLC-97TM1 xenograft model.
Was well tolerated at all tested doses, with no significant dose-limiting toxicity observed, and increased systemic exposure (AUC) correlated with enhanced antitumor efficacy.

Chemical Information

CAS No. 2767642-46-4
Masse moléculaire 418.44
Formule C₂₀H₁₉FN₂O₅S
SMILES

FC1=C2C(OC(C(NS(=O)(C3=CC=CC=C3OCC)=O)=O)=C2)=CC(N4CCC4)=C1
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.